Rojas-Canales, D.Waibel, M.Forget, A.Penko, D.Nitschke, J.Harding, F.Delalat, B.Blencowe, A.Loudovaris, T.Grey, S.Thomas, H.Kay, T.Drogemuller, C.Voelcker, N.Coates, P.2019-04-152019-04-152018Endocrine Connections, 2018; 7(3):490-5032049-36142049-3614http://hdl.handle.net/2440/118548Islet transplantation is currently the only minimally invasive therapy available for patients with type 1 diabetes that can lead to insulin independence; however, it is limited to only a small number of patients. Although clinical procedures have improved in the isolation and culture of islets, a large number of islets are still lost in the pre-transplant period, limiting the success of this treatment. Moreover, current practice includes islets being prepared at specialized centers, which are sometimes remote to the transplant location. Thus, a critical point of intervention to maintain the quality and quantity of isolated islets is during transportation between isolation centers and the transplanting hospitals, during which 20-40% of functional islets can be lost. The current study investigated the use of an oxygen-permeable PDMS microwell device for long-distance transportation of isolated islets. We demonstrate that the microwell device protected islets from aggregation during transport, maintaining viability and average islet size during shipping.en© 2018 The authors 2018. Attribution 4.0 International (CC BY 4.0)hypoxiaisletmicrowellshippingtransplantationJournal article003008310010.1530/EC-17-03490004341279000142-s2.0-85052317401398213Grey, S. [0000-0003-2160-1625]Drogemuller, C. [0000-0001-9770-4845]